Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.1%

3 terminated out of 74 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

15%

11 trials in Phase 3/4

Results Transparency

13%

3 of 24 completed with results

Key Signals

3 with results89% success

Data Visualizations

Phase Distribution

42Total
Not Applicable (16)
Early P 1 (2)
P 1 (5)
P 2 (8)
P 3 (3)
P 4 (8)

Trial Status

Completed24
Recruiting22
Unknown12
Not Yet Recruiting7
Withdrawn4
Terminated3

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (74)

Showing 20 of 20 trials
NCT07570511Not ApplicableNot Yet RecruitingPrimary

Point of Care Testing INR in Antiphospholipid Syndrome

NCT00198068Recruiting

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

NCT07087912Phase 4Recruiting

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

NCT02450396Withdrawn

Pregnancy and Medically Assisted Conception in Rare Diseases

NCT07236762Phase 1Recruiting

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

NCT07172022Phase 2WithdrawnPrimary

A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)

NCT07236801Phase 1Recruiting

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

NCT04402086Recruiting

Rheumatology Patient Registry and Biorepository

NCT03600636Not ApplicableCompletedPrimary

Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter

NCT06614270Not ApplicableRecruiting

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

NCT07301164Early Phase 1Not Yet Recruiting

Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

NCT07212322Not ApplicableNot Yet Recruiting

A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases

NCT05646394RecruitingPrimary

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

NCT00616317RecruitingPrimary

Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study

NCT07251179Not Yet Recruiting

Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies

NCT03969498CompletedPrimary

Evaluation of the Incidence of Cancer in the Follow-up of Women With 3 Consecutive Embryonic Demises Before 10 Weeks or 1 Fetal Death, According to Their Thrombophilia Status, With a Special Focus on Women With an Obstetric Antiphospholipid Symdrome (oAPS)

NCT07163338Not ApplicableRecruitingPrimary

Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)

NCT02833194CompletedPrimary

Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome

NCT02855047CompletedPrimary

The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations

NCT06373926Not ApplicableRecruitingPrimary

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Scroll to load more

Research Network

Activity Timeline